Loading
A phase 2 trial of Moxetumomab pasudotox in Acute lymphoblastic leukaemia, run by Center for International Blood and Marrow Transplant Research, recorded as terminated on the registry.
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation is a phase 2 interventional study registered as NCT02338050 by Center for International Blood and Marrow Transplant Research, with 1 participants recorded, started 2015-05 and due to reach its primary completion in 2020-05. Interventions recorded: Moxetumomab Pasudotox. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).
Linked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Moxetumomab pasudotox and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.